MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
The Formulation & Technology Centre intends to function as a technology storefront, offering advanced formulation and processing solutions to address the growing demand for complex drug formulations
Amgen India investment totals $200 million through 2025
The Alathur facility specializes in the production of Cephalosporin antibiotics
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Wockhardt also saw its revenue from operations increased 3% to Rs. 721 crore during Q3 FY25
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Subscribe To Our Newsletter & Stay Updated
